Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZS-05
- Development stage
- Unknown
- Lead developer
- Zensun
- Modality
- Small Molecules
01
Overview
ZS-05 is a small molecule Vitamin D3 analog and steroid derivative being developed by Zensun for the prevention and treatment of recurrent urinary tract infections (RUTI). The drug acts as an agonist of the Vitamin D receptor (VDR), which triggers the induction and secretion of LL-37, an endogenous antimicrobial peptide, from bladder epithelial cells. By enhancing the innate immune response of the bladder lining, ZS-05 aims to provide a non-antibiotic approach to managing chronic urinary infections. It has received clinical trial approval in China and is currently in Phase 2 clinical development.
- Other names
- Vitamin D3 analogsteroid derivative
02
Targets
VDR (Vitamin D receptor)
Beyond the preview
Go deeper on ZS-05.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZS-05.